The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement: National Consensus Group Comprises Cardiologists, Nephrologists, and Diabetologists from India in a National Meet at New Delhi held on 22nd May 2022
Hirday Kumar Chopra,Gurpreet S Wander,Chandrashekhar K Ponde,Navin C Nanda,Dinesh Khullar,K Venugopal,Saumitra Ray,Tiny Nair,D S Rana,Vijay Kher,Jps Sawhney,R R Kasliwal,Jabir Abdullakutty,Rabin Chakraborty,Praveen Chandra,Sandeep Bansal,Viveka Kumar,Arvind K Pancholia,Aditya Kapoor,Sunil Prakash,Anil Saxena,Vishal Rastogi,Vinod Sharma,Y K Arora,Arup Dasbiswas,Mohan Bhargava,Aparna Jaswal,Kartikeya Bhargava,Mona Bhatia,Ashok K Omar,Narendra Nath Khanna,Rajiv Passey,Dilip Bhalla,I B Vijayalakshmi,Anil Kumar Bhalla,Asha Moorthy,Harmohander S Isser,S S Mishra,Satyanarayan Routray,Vivek Tandon,Ajay Sinha,Manish Bansal,Praveen Jain,Ramesh Hotchandani,Dharmendra Jain,V K Katyal,Sanjiv Gulati,Rohit Tandon,Shalini Jaggi,Blessy Sehgal,Vitull Gupta,Rahul Mehrotra,N C Krishnamani,S N Pathak,M S Yadav,Rajeev Chawla,N R Shastry,Nandini Chatterjee,Shambo Samrat Samajdar,Jyotirmoy Pal,Mangesh Tiwaskar
DOI: https://doi.org/10.59556/japi.71.0400
Abstract:The rapidly increasing burden of hypertension is responsible for premature deaths from cardiovascular disease (CVD), renal disease, and stroke, with a tremendous public health and financial burden. Hypertension detection, treatment, and control vary worldwide; it is still low, particularly in low- and middle-income countries (LMICs). High blood pressure (BP) and CVD risk have a strong, linear, and independent association. They contribute to alarming numbers of all-cause and CVD deaths. A major culprit for increased hypertension is sympathetic activity, and further complications of hypertension are heart failure, ischemic heart disease (IHD), stroke, and renal failure. Now, antihypertensive interventions have emerged as a global public health priority to reduce BP-related morbidity and mortality. Calcium channel blockers (CCB) are highly effective vasodilators. and the most common drugs used for managing hypertension and CVD. Cilnidipine, with both L- and N-type calcium channel blocking activity, is a promising 4th generation CCB. It causes vasodilation via L-type calcium channel blockade and inhibits the sympathetic nervous system (SNS) via N-type calcium channel blockade. Cilnidipine, which acts as a dual L/N-type CCB, is linked to a reduced occurrence of pedal edema compared to amlodipine, which solely blocks L-type calcium channels. The antihypertensive properties of cilnidipine are very substantial, with low BP variability and long-acting properties. It is beneficial for hypertensive patients to deal with morning hypertension and for patients with abnormal nocturnal BP due to exaggerated sympathetic nerve activation. Besides its BP-lowering effect, it also exhibits organ protection via sympathetic nerve inhibition and renin-angiotensin-aldosterone system inhibition; it controls heart rate and proteinuria. Reno-protective, neuroprotective, and cardioprotective effects of cilnidipine have been well-documented and demonstrated.